

state mandates for health education,
23:5-7, 23:13, 23:15-16, 23-18

state smoking laws, 21:27-28

LEUKEMIA

(See also **NEOPLASMS**)

benzene and, 14:51

LEUKOCYTES

cell count in cigar and pipe smokers,
12:81

cell count in ex-smokers, 12:81

cell count in smokers vs. nonsmokers,
12:79-82

chemotaxis in smokers vs. nonsmokers,
12:82

effect of inhalation and smoking levels
on cell count, 79-82

granular, levels in smokers, 10:20

LEUKOPLAKIA

(See also **MOUTH NEOPLASMS**)

betel chewing and, 5:41

bidi smoking and, 5:41

snuff in etiology of, 13:40

tobacco chewing and, 5:41

tobacco chewing in etiology of,
13:40-41

LIFE EXPECTANCY

(See also **MORTALITY**)

definition, 2:11

effect of smoking levels in the United
States, 2:12

LIFE SKILLS TRAINING

antismoking education component,
20:11

LIP NEOPLASMS

(See also **MOUTH NEOPLASMS**)

alcohol consumption and smoking
and, 5:41

pipe smoking and, 1:27

pipe smoking in etiology of, 13:21

relative risk in cigarette vs. cigar vs.
pipe smokers, 13:22

LIPIDS

effect of smoking on metabolism,
12:65

LIVER

function, effect of aromatic hydrocarbons,
12:7-8

organ weight in smokers vs. nonsmokers,
12:9

LOBELINE

nicotine substitute, 19:16-17

LOCUS OF CONTROL

academic achievement and, 20:22

cessation of smoking and, 18:18

maintenance of smoking and, 18:9

Low-tar cigarettes

See **CIGARETTES, LOW-TAR**

Lung diseases

See **BRONCHOPULMONARY DISEASES; BYSSINOSIS; CHRONIC OBSTRUCTIVE LUNG DISEASES; RESPIRATORY TRACT DISEASES**

LUNG FUNCTION

(See also **RESPIRATORY FUNCTION TESTS**)

effect of carbon monoxide exposure,
11:27-28

effect of cessation of smoking, 6:22-23

effect of cigar smoking, 13:34-35,
13:38

effect of nicotine, 14:90

effect of passive smoking in asthmatic patients, 10:22

effect of pipe smoking, 13:34-35,
13:38

effect of smoking, 6:22, 14:90

effect of smoking, summary of findings,
1:18

effect of smoking levels, 6:22

sex ratio, 6:21-22

in smokers vs. nonsmokers, 6:21

in smokers vs. nonsmokers vs. ex-smokers,
6:23

smoking in chlorine workers and,
7:10

smoking in coal miners and, 7:9

smoking in cotton workers and, 7:9
in white, black and oriental smoking
and nonsmoking men and women,
6:21

LUNG NEOPLASMS

(See also **BRONCHIAL NEOPLASMS; RESPIRATORY TRACT NEOPLASMS**)

air pollution in etiology of, 5:25-27

animal models, 5:29-31

aryl hydrocarbon hydroxylase inducibility and, 5:57

asbestos and smoking in etiology of,
5:28

carcinoembryonic antigen test in diagnosis of, 12:61

chloromethyl ethers and smoking in
etiology of, 5:29

in chloromethyl ether workers, 7:16
cigar and pipe smoking and, summary of findings, 1:28
cigar smoking in etiology of, 13:28
effect of age began smoking on mortality ratio, 13:14
effect of cessation of smoking on risk and mortality ratios, 5:24-26
effect of filtered vs. unfiltered cigarettes on risk, 5:16, 5:18-19
effect of inhalation on mortality ratio, 5:14-15
effect of low tar and nicotine cigarettes on mortality ratio, 5:15-17
effect of smoking levels on mortality ratio, 5:13
effect of smoking levels on risk, 5:12-13, 5:16, 5:18-19
effect of smoking on histologic type, 5:23-24
effect of smoking on mortality rates, 5:9-11
heredity and, 5:23
histologic types, 5:23-24
induced by benzo(a)pyrene in hamsters, 5:30
induced by nitrosamines in animals, 5:30
mortality in asbestos workers, 7:11-12
mortality rates in cigar vs. pipe smokers, 5:23
mortality rates in women, 5:16-18, 5:20-
mortality ratio in cigar vs. cigarette vs. pipe smokers, 13:26
mortality rate trends in Great Britain and the United States, 5:10-11
mortality ratio in smokers vs. nonsmokers, 5:11-12
nickel and smoking in etiology of, 5:28
occupational exposures and smoking in etiology of, 5:27-29, 7:17
relative risk in cigar vs. cigarette vs. pipe smokers, 13:29-30
role of pulmonary alveolar macrophages, 5:31
smoking and, summary of findings, 1:16
smoking and occupational risk in whites and nonwhites, 7:17

smoking in asbestos workers and, 7:11-13
smoking in etiology of, historical perspective, 5:9
smoking in uranium miners and, 7:14
in smoking vs. nonsmoking twins, 5:23
uranium and smoking in etiology of, 5:28
in urban vs. rural areas, 5:25-27

LUNGS

(See also **RESPIRATORY SYSTEM**)

air pollution and pathology in smokers vs. nonsmokers, 6:36
effect of cigar smoking, 13:35
effect of pipe smoking, 13:35
effect of smoke inhalation in dogs, 14:76
effect of smoke inhalation in monkeys, 14:76
effect of smoking, 6:18
effect of smoking, summary of findings, 1:18-19
effect of smoking levels on pathology, 6:24-27
effect of smoking on pathogenesis, 6:25-26
enzyme induction of emphysema, 6:28
nicotine absorption, 14:85
organ weight in smokers vs. nonsmokers, 12:9

LYMPHOCYTES

B and T, in smokers vs. nonsmokers, 6:31
effect of smoking, 10:19
effect of tobacco smoke in mice, 10:19
effect of tobacco smoke on immune function, 10:17

MACROPHAGES, ALVEOLAR

(See also **PHAGOCYTOSIS**)

in bronchial fluid of smokers, 6:28
count in smokers vs. nonsmokers, 6:29
effect of cigarette smoke, 6:29-30
effect of cigarette smoke on phagocytic activity, 10:17
effect of tobacco smoke, 10:15-16
effect of tobacco smoke on count and ultrastructure, 10:16

effect of smoke inhalation in dogs, 14:76
effect of smoke inhalation in monkeys, 14:76
elastase release in smokers vs. nonsmokers, 6:30
in lung neoplasm etiology, 5:31
protease activity in smokers vs. nonsmokers, 6:29
in smokers vs. nonsmokers, 6:31
Mainstream smoke
See **SMOKE, CIGARETTE MAINSTREAM; SMOKE STREAMS**
MALEIC HYDRAZIDE
hydrazine levels and, 14:41
structural formula, 14:62
tobacco curing and, 14:47
MALES
(See also **SEX RATIO**)
smoking prevalence, A:11, A:12-13, A:17-18
MARIJUANA
(See also **CANNABIS; DRUG ABUSE**)
correlation with tobacco smoking, 18:14
effect on enzyme activity, 12:42-43
effect on pharmacokinetics, 12:42-43
effect on pregnant animals, 8:53
MATERNAL-FETAL EXCHANGE
aromatic hydrocarbons in animals, 8:66
benzo(a)pyrene in animals, 8:66
carbon monoxide in sheep, 8:59
carbon monoxide in sheep and dogs, 8:58
nicotine in animals, 8:54
Maternal smoking
See **SMOKING, MATERNAL**
Maximum mid-expiratory flow rate measurements
See **RESPIRATORY FUNCTION TESTS**
MECAMYLAMINE
nicotine antagonist, 16:8-9
MEDICAL STUDENTS
antismoking education, 22:17-18
perceptions of physicians' smoking habits, 22:7
smoking habits, 18:8, 22:18
MEDITATION
in modification of smoking behavior, 19:22

Men
See **MALES**
MEPERIDINE
total clearance in smokers vs. nonsmokers, 12:39
MEPROBAMATE
cessation aid, 19:17
MERCURY
(See also **METALS**)
levels in smokers vs. nonsmokers, 12:73
smoking and occupational exposure, 7:7
MESOTHELIOMA
(See also **CARCINOGENESIS; NEOPLASMS**)
smoking and asbestos exposure and, 7:12
METABOLISM
(See also **NICOTINE METABOLISM**)
carbon monoxide in maintenance of smoking habit, 15:17
effect of smoking on carbohydrates, lipids and proteins, 12:65
effect of tobacco smoke on food constituents and additives, 12:75-76
nicotine in maintenance of smoking habit, 15:16
nicotine, in smokers vs. nonsmokers, 15:9
tar, in maintenance of smoking habit, 15:17
METALS
(See also **CADMIUM; CALCIUM; LEAD; MERCURY; NICKEL**)
cardiovascular diseases and, 4:62
in cigarette smoke as carcinogens, 14:59-60
levels in particulate phase cigarette smoke, 14:59
levels in smokers vs. nonsmokers, 12:73-74
in tobacco smoke, 14:58-59
METHYL PARATHION
smoking and occupational exposure, 7:7
METHYLCHOLANTHRENE
(See also **AROMATIC HYDROCARBONS**)
effect on aryl hydrocarbon hydroxylase activity in rats, 12:28-29
effect on enzyme activity, 12:21-22

effect on phenacetin pharmacokinetics in rats, 12:28-29
effect on RNA metabolism, 12:21-22
effect on theophylline metabolism in rats, 12:32
in oral neoplasm induction in hamsters, 5:42

METHYLENE CHLORIDE

occupational hazards, 7:8-9

MORBIDITY

(See also **MORTALITY**)

bed disability in smokers vs. nonsmokers, 3:12
bronchitis and emphysema in the United States, 6:20
coronary heart disease in ex-smokers, 4:38
effect of cessation of smoking, summary of findings, 1:12-13
effect of smoking, 3:5
effect of smoking, summary of findings, 1:12-13
effect of smoking on acute conditions, 3:6
effect of smoking on chronic conditions, 3:6-7
findings of NCHS National Health Interview Survey, 1:12-13
incidence of acute conditions in smokers vs. nonsmokers vs. ex-smokers, 3:9
peptic ulcer in the United States, 9:17
prevalence rate of chronic conditions, 3:6-7
smoking and lung neoplasms and occupational risk, 7:17
work-days lost, 3:8-9

MORBIDITY RATIO

angina pectoris, effect of smoking levels, 4:48
coronary heart disease in ex-smokers, 4:28-31, 4:34-35
coronary heart disease in smokers vs. nonsmokers, 4:27-33, 4:36-37

MORTALITY

(See also **EXCESS DEATHS; FETAL MORTALITY; INFANT MORTALITY; LIFE EXPECTANCY; MORBIDITY; PERINATAL MORTALITY**)

annual probability of dying in smokers vs. nonsmokers vs. ex-smokers, 2:30-34
bronchitis in cigar vs. cigarette vs. pipe smokers, 13:34
chronic obstructive lung disease in smokers, 2:41, 6:9
chronic obstructive lung disease in smokers vs. nonsmokers vs. ex-smokers, 6:10
cigar and pipe smokers vs. ex-smokers, 13:8
cigar vs. cigarette vs. pipe smokers, 13:13-14
effect of age began smoking, 2:19
effect of cigar smoking, 2:30, 2:35-37
effect of environmental factors, 2:42
effect of heredity in smoking related disease, 2:41-42
effect of inhalation, 2:20
effect of inhalation in cigar and pipe smokers, 13:18
effect of nicotine and tar content, 2:22
effect of pipe smoking, 2:30, 2:35-37
effect of smoking in the United States, 2:9
effect of smoking in women, 2:25
effect of smoking levels in cigar and pipe smokers, 13:14-16
effect of social factors, 2:42
effect of years since quitting in ex-smokers, 2:27-34, 2:35
emphysema in cigar vs. cigarette vs. pipe smokers, 13:34
epidemiological studies, 2:12-15
esophageal neoplasms in cigar vs. cigarette vs. pipe smokers, 13:24
ex-smokers, 2:26-30
methods of measuring, 2:10-11
peptic ulcer in cigar vs. cigarette vs. pipe smokers, 13:38
peptic ulcer in smokers, 2:41, 9:10
peptic ulcer in smokers vs. nonsmokers, 9:17
respiratory tract infections in smokers, 2:41

risk from pregnancy and childbirth vs. oral contraceptive use, 12:52
smoking and lung neoplasms and asbestos exposure, 7:11

MORTALITY RATES

age groups in the United States, 2:11
cerebrovascular disease in male vs. female smokers, 4:51
circulatory diseases, effect of oral contraceptives and smoking, 12:51
coronary heart disease in ex-smokers, 4:38
definition, 2:10-11
effect of cigar and pipe smoking, summary of findings, 1:27
effect of less hazardous cigarettes, 2:25
lung neoplasms and smoking, summary of findings, 1:16
lung neoplasms, effect of smoking, 5:9-11
lung neoplasms in cigar and pipe smokers, 5:23
lung neoplasms in women, 5:16-18, 5:20
lung neoplasms, trends in Great Britain and the United States, 5:10-11
myocardial infarct in smokers vs. nonsmokers, 4:35-36
smokers vs. nonsmokers, 2:15
thrombosis in smokers vs. nonsmokers, 4:59

MORTALITY RATIO

age groups in the United States, 2:11, 2:17-18
age groups worldwide, 2:17-18
aortic aneurysm, effect of smoking levels, 4:55
bladder neoplasms in smokers, 5:45-46
cardiovascular diseases in cigar vs. cigarette vs. pipe smokers, 13:33-34
cardiovascular diseases in smokers, 2:39
cardiovascular diseases in smokers vs. nonsmokers in Japan, 4:21, 4:34-35
cause-specific, effect of smoking, 2:37-41

cerebrovascular disease in cigar vs. cigarette vs. pipe smokers, 13:33
cerebrovascular disease in male vs. female smokers, 4:51
chronic obstructive lung disease, 6:10
chronic obstructive lung disease in cigar vs. cigarette vs. pipe smokers, 13:35
cigar vs. cigarette vs. pipe smokers, 2:30, 2:35-36
cigarette vs. cigar vs. pipe vs. mixed smokers, 13:14
coronary heart disease in cigar vs. cigarette vs. pipe smokers, 13:33-34
coronary heart disease in smokers, 2:39
coronary heart disease in ex-smokers, 4:34-35
coronary heart disease in smokers vs. nonsmokers, 4:22-26, 4:36-37
definition, 2:10
effect of age began smoking, 2:19-22
effect of cigar and pipe smoking, 1:11-12
effect of combined tobacco product use, 2:39
effect of inhalation, 2:22-24
effect of inhalation, smoking duration and smoking levels in women, 2:26-27
effect of less hazardous cigarettes, 1:11, 2:23-25
effect of reasons for quitting in ex-smokers, 2:27-29
effect of smoking, summary of findings, 1:10-12
effect of smoking duration, 2:17-19
effect of smoking duration in cigar smokers, 2:37
effect of smoking duration in ex-smokers, 2:28-29
effect of smoking duration in pipe smokers, 2:38
effect of smoking levels, 2:15-18, 2:22
effect of smoking levels in cigar smokers, 13:15-17, 2:36-37
effect of smoking levels in ex-smokers, 2:28-29
effect of smoking levels in pipe smokers, 2:36-38, 13:15-17

esophageal neoplasms in cigar and pipe smokers, 5:43
esophageal neoplasms in cigar vs. cigarette vs. pipe smokers, 13:25
esophageal neoplasms in smokers, 5:42-43
ex-smokers, 2:35
kidney neoplasms in smokers, 5:48-49
laryngeal neoplasms in cigar vs. cigarette vs. pipe smokers, 13:24
laryngeal neoplasms in smokers, 5:32-33
lung neoplasms, effect of age began smoking, 5:13-14
lung neoplasms, effect of cessation of smoking, 5:24-26
lung neoplasms, effect of inhalation, 5:14-15
lung neoplasms, effect of low tar and nicotine cigarettes, 5:15-17
lung neoplasms, effect of smoking levels, 5:13
lung neoplasms in cigar vs. cigarette vs. pipe smokers, 13:26-28
lung neoplasms in smokers vs. non-smokers, 5:11-12
lung neoplasms in smoking women, 5:20-22
neoplasms, effect of cigar and pipe smoking, 13:20
neoplasms in smokers, 2:38
oral neoplasms in cigar vs. cigarette vs. pipe smokers, 13:21-23
oral neoplasms in smokers, 5:39-40
pancreatic neoplasms in smokers, 5:50-52
pharyngeal neoplasms in cigar vs. cigarette vs. pipe smokers, 13:23
in smoking twins, 2:42
sudden cardiac death, effect of smoking levels, 4:43

MORTALITY RISK
infant, and gestational age in smoking vs. nonsmoking mothers, 8:43, 8:45
infant, effect of maternal smoking, age, parity, and education, 8:33
infant, effect of maternal smoking, age, parity, and social class, 8:31
infant, synergism of maternal smoking and other risk factors, 8:35
infants of smokers vs. nonsmokers, 8:34

MOTIVATION

(See also **BEHAVIOR**)

cessation of smoking and, 18:19-20
emotional influences in smoking behavior, 16:6
maintenance of smoking and, 18:10-13, 18:15-17
smoking habit in developing countries and, 18:24
smoking habit in the Solomon Islands and, 18:24

MOUTH

nicotine absorption, 14:85

MOUTH MUCOSA

(See also **LEUKOPLAKIA**)

effect of snuff in women, 13:39-40

MOUTH NEOPLASMS

(See also **LEUKOPLAKIA; LIP NEOPLASMS; TONGUE NEOPLASMS**)

alcohol consumption and smoking and, 5:40-41
cigar and pipe smoking and, summary of findings, 1:27

MUCOCILIARY SYSTEM

(See also **CILIARY ACTIVITY; CILLATOXICITY**)

effect of cigarette smoke, 6:32-33, 10:15

MULTICOMPONENT TREATMENT

(See also **CESSATION OF SMOKING**)

in cessation of smoking, 16:16-17, 16:19
evaluation, 19:36
modification of smoking behavior, 19:27-28
self-administered, 19:29

MULTIPLE RISK FACTOR INTERVENTION TRIAL

effect on cessation of smoking, 19:15

MUTAGENS

in atherosclerosis etiology, 4:10

MYOCARDIAL INFARCT

(See also **CORONARY HEART DISEASE**)

animal models, 4:20
atherosclerosis in etiology of, 4:19-20
cessation of smoking after, 19:14
effect of oral contraceptives and smoking on risk, 4:60
effect of smoke inhalation in dogs, 14:77

effect of smoking on risk of recurrence or death, 4:37-38
estrogens and smoking and, 12:52
ex-smokers, 4:21
ischemia and, 4:19-20, 4:39-40
morbidity ratios in ex-smokers, 4:34
morbidity ratios in smokers vs. non-smokers, 4:27-33
oral contraceptives and smoking and, 4:35, 12:51-52
pathogenesis, 4:18-20
research needs, 4:40-41
risk factors, 4:20-21
smokers vs. nonsmokers, 4:35-36
smoking in etiology of, 4:21, 4:38-40
smoking vs. nonsmoking women, 12:52
sudden cardiac death and, 4:43

MYOCARDIUM
effect of hypoxia and ischemia, 4:19-20

NAPHTHALENE

in cigarette smoke, 14:51
tobacco pyrolysis and, 14:49

NAPHTHYLAMINES

(*See also* **AROMATIC AMINES**)

pancreatic neoplasms and, 5:51

NATIONAL ASSOCIATION OF SECONDARY SCHOOL PRINCIPALS

statement on school smoking policies, 23:8, 23:11, 23:13

NATIONAL CANCER INSTITUTE

funding of "Know Your Body" Program, 21:20

NATIONAL CENTER FOR HEALTH STATISTICS, 3:5

findings of National Health Interview Survey, 1:12-13

Health and Nutrition Examination Survey, 3:11-12

Health Interview Survey, 3:8-18

NATIONAL CLEARINGHOUSE FOR SMOKING AND HEALTH

definition of smokers and nonsmokers, 23:24

establishment of San Diego Community Laboratory, 20:14

Health Consequences of Smoking reports, 1:9-10

smoking prevalence in adults by educational level, A:14-16

smoking prevalence in adults by family income, A:14-16
survey of adolescent smoking, 17:7-8
survey of adult tobacco use, 18:19, 22:6
survey of cigar and pipe smoking in the United States, 13:8-9
survey of smoking attitudes of health professionals, 22:7
survey of smoking habits of health professionals, 22:12-13
survey of tar and nicotine levels of cigarette brands, 3:11
survey of teenage smoking, A:14
training of health educators, 23:32

NATIONAL INSTITUTES OF HEALTH

respiratory disease study, 17:15

NATIONAL INTERAGENCY COUNCIL ON SMOKING AND HEALTH

funding of youth antismoking projects, 20:24

research guidelines, 19:5-8, 21:16-17

NATIONAL PARENT-TEACHER ASSOCIATION

health education programs, 21:21, 21:25

NEONATAL MORTALITY

(*See also* **INFANT MORTALITY; MORTALITY RISK; PERINATAL MORTALITY**)

effect of maternal smoking and gestational age, 8:43

effect of maternal smoking and other factors, 8:41

etiology of perinatal death in smokers vs. nonsmokers, 8:37

maternal smoking and, research needs, 8:76

maternal smoking levels and, 8:39-40

NEOPLASMS

(*See also* **CARCINOGENESIS; LEUKEMIA; MESOTHELIOMA**)

aryl hydrocarbon hydroxylase inducibility and smoking and, 5:57

cigar and pipe smoking and, summary of findings, 1:27-28

effect of smoking on mortality ratio, 2:38

induced by polonium-210 in Syrian hamsters, 14:61

induced by tobacco smoke in animals, 1:17

- mortality ratio in cigar and pipe smokers, 13:20
- nitrosamines in etiology of, 12:74
- in progeny after maternal exposure to benzo(a)pyrene in mice, 8:67
- smoking and, summary of findings, 1:15-17
- smoking and asbestos exposure and, 7:11-13
- smoking in etiology of, historical perspective, 5:9
- Neoplasms, bronchial**
See **BRONCHIAL NEOPLASMS**
- Neoplasms, esophageal**
See **ESOPHAGEAL NEOPLASMS**
- Neoplasms, laryngeal**
See **LARYNGEAL NEOPLASMS**
- Neoplasms, lip**
See **LIP NEOPLASMS**
- Neoplasms, lung**
See **LUNG NEOPLASMS**
- Neoplasms, mouth**
See **MOUTH NEOPLASMS**
- Neoplasms, pancreatic**
See **PANCREATIC NEOPLASMS**
- Neoplasms, pharyngeal**
See **PHARYNGEAL NEOPLASMS**
- Neoplasms, oral**
See **ORAL NEOPLASMS**
- Neoplasms, tongue**
See **TONGUE NEOPLASMS**
- NEUROTICISM**
(See also **ANXIETY**; **STRESS**)
- cessation of smoking and, 18:17-18
- maintenance of smoking and, 18:7-9
- smoking characteristics and, 18:13
- NICKEL**
(See also **METALS**)
- levels in tobacco smoke, 14:59
- and smoking in lung neoplasm etiology, 5:28
- NICOTINE**
(See also **ALKALOIDS, TOBACCO**)
- absorption by involuntary smoking, 11:24
- addiction, 16:7-9, 18:12
- in allergy induction, 10:22
- in amniotic fluid after maternal injection in animals, 8:54
- in atherosclerosis induction in animals, 4:16
- cardiovascular diseases and, 14:79
- carotid blood levels after oral administration, 14:86
- central nervous system receptor sites, 16:18-19
- dependence and, 14:97
- effect of cigar smoke inhalation on absorption, 13:16-17
- effect of fetal injection in utero in animals, 8:55
- effect of maternal injection on fetus in animals, 8:54-57
- effect of maternal injection on nursing kittens, 8:49
- effect of maternal injection on offspring in rats, 8:10-11
- effect of maternal injection on psychomotor function in newborn animals, 8:57
- effect of self-administration on smoking habit, 15:12
- effect of smoking characteristics on absorption, 14:87
- effect on angina pectoris, 4:39
- effect on antidiuretic hormone secretion, 12:37, 12:54
- effect on arousal, 15:11
- effect on arteries in rabbits, 4:56
- effect on behavior in monkeys, 15:12
- effect on behavior in rats, 15:11, 15:18
- effect on birth weight in animals, 8:53
- effect on blood lipid levels in animals, 4:61
- effect on blood pressure and heart rate, 4:58, 14:87, 14:91
- effect on cardiovascular system, 12:52-54, 14:89
- effect on cardiovascular system in animals, 8:55-56
- effect on cardiovascular system in animals with myocardial infarct, 4:45
- effect on catecholamines in rats, 14:88
- effect on central nervous system, 14:89
- effect on cerebrovascular circulation, 4:50
- effect on corticosteroid secretion, 12:40
- effect on drug assays, 12:34

effect on enzyme activity, 12:27-28, 14:87
effect on enzyme activity in rat intestines, 12:76
effect on exercise induced angina pectoris, 4:47
effect on fetal and newborn central nervous system, 8:57
effect on fetal and newborn central nervous system in animals, 8:56
effect on fetus, research needs, 8:79
effect on fetus and breastfed infants of smoking mothers, 8:51
effect on free fatty acids, 12:40, 14:90
effect on gastric secretion in cats, 9:12-13
effect on gastric secretion in man, 9:13-14
effect on heart function in animals with coronary heart disease, 4:40
effect on hormones in monkeys, 15:20
effect on immunoglobulins, 6:31
effect on ischemia, 4:39
effect on lactation in cats, 8:49
effect on lactation in cows, 8:49
effect on lactation in rats, 8:49
effect on lung function, 14:90
effect on lymphocytes in mice, 10:19
effect on nitrosamine biosynthesis, 12:75
effect on pancreatic secretion in dogs, 5:53, 9:14-15
effect on patellar reflex, 14:92
effect on pharmacokinetics, 12:27-28
effect on psychomotor performance, 16:8
effect on pregnant rats, 8:10-11
effect on serum secretin levels, 9:14-15
effect on smoking habit, 15:7-8
effect on smoking habit, summary of findings, 1:30-32
effect on tolerance in rats, 15:16
effect on vitamin C levels in animals, 12:66
in establishing smoking habit, 15:5
excretion under stress, 16:8
induction of hyperglycemia in cats, 14:90
induction of peptic ulcer in cats, 9:12-13

induction of peptic ulcer in rats, 9:12
interactive effect with oxprenolol on blood pressure, 12:54
interactive effect with propranolol on cardiovascular system, 12:53
internal regulation in smokers, 16:13-14
in maintenance of smoking habit, 15:14
maternal-fetal exchange in animals, 8:54
metabolism in maternal and fetal liver in animals, 8:55
metabolism in smokers vs. nonsmokers, 15:9
methods of absorption, 14:85
myocardial infarct and, 4:20
pancreatic neoplasms and, 5:53
pharmacology in cessation of smoking, 14:94, 14:97
protonation and, 14:108
as reinforcer, 16:12, 16:18
relative molar potency in cigarette smoke, 14:96
role as haptens, 10:11
role in alteration of drug metabolism, 12:40
sales weighted average delivery in American cigarettes, 14:111
smoke dosimetry and, 14:75
structural formula, 14:46
summary of physiological effects, 1:30-31

NICOTINE CONTENT
(See also **ALKALOID CONTENT**)
in blood, effect of smoking cigarettes vs. little cigars, 14:87
in blood after oral administration, 14:86
in cigar vs. cigarette smoke, 13:11
in cigarette smoke, 14:45
in cigarettes, health characteristics and, 3:11
in cigarettes vs. little cigars, 14:44-45
in cow's milk after intramuscular injection, 8:49
decrease in modern cigarettes, A:19-20
effect on mortality, 2:22
filters and, 14:104
in milk of lactating smoking vs. non-smoking mothers, 8:50-51

- as smoke inhalation indicator, 14:75
- in urine and plasma of smokers vs. nonsmokers, 11:24
- in urine as measure of tobacco usage, 15:29
- in urine of smokers vs. nonsmokers, 15:29
- NICOTINE CHEWING GUM**
 - in cessation of smoking, 19:16-17
 - in reduction of smoking, 16:8
- NICOTINE-IN-SALIVA TEST**
 - correlation with self-reported smoking, 17:24
- NICOTINE METABOLISM**
 - (See also **METABOLISM**)
 - degree of protonation in relation to pH, 14:86
 - distribution and clearance in rats, 14:79
 - effect of urinary pH on excretion, 14:92-93
 - enzymes and, 14:87
 - pathway, 14:93
 - rate of absorption, 14:92
- NICOTINE METABOLITES**
 - (See also **COTININE; NORNICOTINE**)
 - in cigarette smoke, 14:93-94
 - effect of urinary pH on excretion, 14:92
- NICOTINE REDUCTION**
 - in cigarettes in the United States, 14:44
 - effect on lung neoplasm mortality ratio, 5:15-16
 - methods, 14:114
 - in particulate phase of cigarette smoke, 14:108
- NICOTINE TOXICITY**
 - atherosclerosis and, 14:79
 - effect on heart, 14:78
 - effect on smoke inhalation dosimetry, 14:75
 - hypertension and, 14:79
- NITRIC OXIDE**
 - in blood of smokers vs. nonsmokers, 14:80
 - effect on enzyme activity in rats, 14:81
- NITRILES**
 - levels in cigarette smoke, 14:40
- NITROGEN COMPOUNDS**
 - in cigarette smoke, 14:41
 - in soil, effect on tobacco leaf quality, 14:15-16
- NITROGEN DIOXIDE**
 - effect on antibody response to bacterial vaccines in mice, 12:59
 - effect on respiratory tract in rats, 14:81
- NITROGEN OXIDES**
 - absorption, 14:99
 - cardiovascular diseases and, 4:62
 - content in mainstream cigarette smoke, 14:39
- NITROSAMINE CONTENT**
 - in cigarette smoke, 14:39, 14:45
 - effect of curing and fermentation, 14:45
 - effect of homogenized leaf curing, effect of smoking in enclosed spaces, 11:25
 - reduction in gas phase cigarette smoke, 14:107
 - reduction in particulate phase cigarette smoke, 14:112
 - in tobacco and tobacco smoke, 12:74
- NITROSAMINES**
 - (See also **DIMETHYLNITROSAMINE**)
 - agricultural practices and, 14:107
 - biosynthesis in smokers, 12:74-75
 - bladder neoplasms and, 5:47
 - in chewing tobacco, 14:45
 - effect of maternal injection on tracheal neoplasms in hamster offspring, 8:50
 - effect of nicotine on biosynthesis, 12:75
 - in esophageal neoplasm induction in animals, 5:44
 - in lung neoplasm induction in hamsters, 5:30
 - in neoplasm etiology, 12:74
 - in pancreatic neoplasm induction in hamsters, 5:51-53
 - precursors, 14:41
 - quantification by thermal energy analyzer, 14:11
 - in respiratory tract neoplasm induction in animals, 5:30
 - structural formulae, 14:46

NONSMOKERS

(*See also* **SMOKERS VS. NON-SMOKERS**)

- absorption of tobacco smoke constituents, 11:6
- annoyance caused by tobacco smoke, 11:25
- annual probability of dying, 2:30-34
- effect of involuntary smoking, 11:5, 11:15, 11:28
- effect of involuntary smoking on carboxyhemoglobin levels, 11:21, 11:23
- effect of tobacco smoke, 11:25
- median carboxyhemoglobin levels by location, 11:23
- nicotine absorption by involuntary smoking, 11:24
- perception of health status, 3:14-15
- rights, 16:19-20, 21:14, 21:18
- typology, 18:13

NORNICOTINE

(*See also* **NICOTINE METABOLITES**)

- relative molar potency in cigarette smoke, 14:96
- structural formula, 14:46

NORTRIPTYLINE

- plasma concentrations in smokers vs. nonsmokers, 12:39

NOSE IRRITATION

- effect of smoking in enclosed spaces, 11:26

NURSES

- role in cessation decision, 21:12, 21:14, 22:17
- smoking habits, 22:12-14

NURSING HOMES

- smoking policies, 22:20

OBESITY

(*See also* **BODY WEIGHT**)

- cessation of smoking and, 12:67

OBSTRUCTIVE AIRWAY DISEASES

(*See also* **BRONCHITIS; BRONCHOPULMONARY DISEASES;**

CHRONIC OBSTRUCTIVE LUNG DISEASE; EMPHYSEMA)

- smoking in cotton workers and, 7:9-10
- smoking in fire fighters and, 7:10-11
- smoking in miners and, 7:9

OCCUPATIONAL DISEASES

(*See also* **ASBESTOSIS; BYSSINOSIS; NEOPLASMS; POLYMER FUME FEVER**)

- asbestosis, 7:11-13
 - byssinosis, 7:9
 - "Monday morning fever", 7:9
 - polymer fume fever, 7:5-6
- ## **OCCUPATIONAL EXPOSURE**
- bronchopulmonary diseases and, 1:19, 6:36, 7:13
 - interactive effect with smoking, summary of findings, 1:19-20
 - smoking and bladder neoplasms and, 5:47
 - smoking and pancreatic neoplasms and, 5:47
 - and smoking in lung neoplasm etiology, 5:27-29
 - smoking levels and health risk, 7:17

OCCUPATIONAL HAZARDS

- alpha irradiation from radon, 7:14
- aromatic amines, 7:16
- asbestos, 7:11-13
- beta radiation, 7:10
- carbon monoxide, 7:8
- chlorine, 7:10
- chloromethyl ether, 7:15-16
- dust, coal, 7:9
- dust, cotton, 7:9
- dust, gold, 7:15
- effect of smoking and recommendations for research, 7:19
- hydrogen cyanide, 7:7-8
- rubber, 7:13

OCCUPATIONS

- asbestos workers, 5:28, 7:11-13
- battery factory workers, 7:15
- benzene workers, 14:51
- blast furnace workers, 7:8
- blue- and white-collar workers, 7:17
- bronchitis in smokers vs. nonsmokers and, 6:39
- chemists, 5:51
- chlorine workers, 7:10
- chloromethyl ether workers, 5:29, 7:15-16
- coal gas workers, 7:16
- coal miners, 13:35
- cotton workers, 7:9
- electroplaters, 7:7
- fire fighters, 7:10-11
- gold miners, 7:15

industrial workers, 22:16-17, 22:19
insulation workers, 7:11
methylene chloride workers, 7:8-9
miners, 7:9
nickel workers, 5:28
rubber workers, 7:13
smoking prevalence rates and, 18:16,
A:16
steelworkers, 7:8
telephone workers, 6:37
tobacco workers, female, 8:9
uranium miners, 5:28, 7:14, 12:90

OFFICE ON SMOKING AND HEALTH
information dissemination function,
23:27-28

Olefins
See ALKENES

ONTARIO PERINATAL MORTALITY STUDY, 8:33-35, 8:37, 8:39-42, 8:45

ORAL NEOPLASMS, 5:39-42
(*See also* LEUKOPLAKIA; LIP NEOPLASMS; MOUTH NEOPLASMS; TONGUE NEOPLASMS)
alcohol consumption and smoking and, 5:40-41
animal models, 5:41-42
betel chewing in etiology of, 13:40-41
cigar and pipe smoking and, 5:39
induced by benzo(a)pyrene in hamsters, 5:42
induced by dimethyl benzanthracene in hamsters, 5:42
induced by methylcholanthrene in hamsters, 5:42
mortality ratio in cigarette vs. cigar vs. pipe smokers, 13:21-23
mortality ratio in smokers, 5:39-40
smoking and, summary of findings, 1:17
smoking in etiology of, 5:39-42
snuff in etiology of, 13:39-40
tobacco chewing and, 5:39-40
tobacco chewing in etiology of, 13:40-41

ORALITY
smoking habit and, 18:9

ORGANOTIN
smoking and occupational exposure, 7:7

OSTEOPOROSIS
smokers vs. nonsmokers, 12:67

OXPRENOLOL
interactive effect with nicotine on blood pressure, 12:54

OXYGEN TENSION
effect of maternal and fetal carboxyhemoglobin levels, 8:64

OXYGEN TRANSPORT
effect of carbon monoxide in mother and fetus, 8:61

OXYHEMOGLOBIN SATURATION CURVES
maternal and fetal, effect of carbon monoxide levels in blood, 8:62-63, 8:72

PANCREATIC NEOPLASMS
animal models, 5:51-53
correlation with bladder neoplasms, 5:47
diet and, 5:51
effect of smoking levels on mortality and risk ratios, 5:50, 5:52
effect of smoking and occupational exposure, 7:17
induced by nitrosamines in hamsters, 5:51-53
mortality and risk ratios in male vs. female smokers, 5:50-52
naphthylamines and, 5:51
nicotine and, 5:53
occupational exposure and, 5:51
smoking and, summary of findings, 1:17

PANCREATIC SECRETION
effect of nicotine in animals and man, 9:14-15
effect of nicotine in dogs, 5:53
effect of smoking, 9:14-15

Paper, cigarette
See CIGARETTE PAPER

Parental smoking
See SMOKING, PARENTAL

PARKINSONISM
smoking and, 2:41

PARTICULATE PHASE, CIGARETTE SMOKE
(*See also* TARS, TOBACCO; TOTAL PARTICULATE MATTER)
aromatic hydrocarbons reduction, 14:109
component levels, 15:6
definition, 14:35, 14:38
determination of tar levels, 14:43

levels of toxic compounds, 14:64-65
levels of metals, 14:59
nicotine reduction, 14:108
nitrosamines reduction, 14:112
ratio of constituents in main- vs.
sidestream smoke, 11:6
polonium-210 reduction, 14:113
tar reduction methods, 14:110
toxicity reduction, 14:108
toxicity reduction methods, 14:114

Passive smoking
See INVOLUNTARY SMOKING

Peak expiratory flow measurements
See RESPIRATORY FUNCTION TESTS

PEER GROUPS
influence on cessation of smoking, 18:21
influence on drug abuse in adolescents, 18:14
influence on initiation of smoking, 16:5
influence on smoking habit in adolescents, 17:10, 17:14, 21:13-14
youth-to-youth antismoking programs, 20:9

PENTAZOCINE
dosage requirements in smokers vs. nonsmokers, 12:36

Peptic ulcer
See ULCER, PEPTIC

PERINATAL MORTALITY
(*See also* INFANT MORTALITY; MORTALITY RISK; NEONATAL MORTALITY)
effect of maternal smoking, summary of findings, 1:22
gestational age and risk in smoking vs. nonsmoking mothers, 8:43
maternal smoking in etiology of, 12:67
maternal smoking levels and, 8:39-40

PERIPHERAL VASCULAR DISEASE
animal models, 4:53
clinical and pathological features, 4:52
research needs, 4:54
risk factors, 4:52
smoking and, summary of findings, 1:14-15
smoking and, 4:53-54
smoking vs. nonsmoking diabetics, 4:53

PERSONALITY
(*See also* BEHAVIOR)
cessation of smoking and, 18:17-18, 18:21-22
effect on pharmacokinetics, 12:40-41
effect on success rates for cessation of smoking, 15:24
maintenance of smoking and, 18:5-10
maternal smoking and, 8:26
and recidivism, 19:31
and smoking habits in adolescents, 17:16

PESTICIDE RESIDUES
hydrazine formation, 14:41
reduction in tobacco, 14:61
structural formulae, 14:62
in tobacco leaf, 14:18
in tobacco smoke, 12:75
toxic effects in smokers, 12:75

pH
cigar vs. cigarette vs. pipe smoke, 13:15-16

PHAGOCYTOSIS
(*See also* MACROPHAGES, ALVEOLAR)
effect of tobacco smoke, 6:30-31
role in lung neoplasm etiology, 5:31

PHARMACISTS
antismoking advice to customers, 22:17
as role models, 22:8-9
smoking habits, 22:12

PHARMACODYNAMICS
(*See also* DRUG METABOLISM; PHARMACOLOGY)
absence of smoking effect, 12:37-39
clinical importance of smoking history in drug monitoring, 12:41-42
dexamethasone, effect of smoking, 12:37
diazepam, effect of smoking, 12:38
effect of smoking, 12:27-44
effect of smoking, summary of findings, 1:25-26
furosemide, effect of smoking, 12:37
propranolol, effect of smoking, 12:37
research needs, 12:44
smokers vs. nonsmokers, 12:36-37

PHARMACOKINETICS
(*See also* DRUG METABOLISM; PHARMACOLOGY)
absence of smoking effect, 12:37-39

antipyrine, in smokers vs. nonsmokers, 12:29-31
caffeine, effect of aromatic hydrocarbons in rats, 12:32-33
clinical importance of smoking history in drug monitoring, 12:41-42
effect of behavior and personality, 12:40-41
effect of marijuana, 12:42-43
effect of smoking, 12:27-44
effect of smoking, summary of findings, 1:25-26
ethanol, in smokers vs. nonsmokers, 12:39
glutethimide, in smokers vs. nonsmokers, 12:33
imipramine, effect of smoking, 12:33
meperidine, in smokers vs. nonsmokers, 12:39
nortriptyline, in smokers vs. nonsmokers, 12:39
pentazocine, in smokers vs. nonsmokers, 12:36
phenacetin, effect of cigarette smoke in rats, 12:28-29
phenacetin, in smokers vs. nonsmokers, 12:28-29
phenytoin, in smokers vs. nonsmokers, 12:38
research needs, 12:44
theophylline, effect of methylcholanthrene in rats, 12:32
theophylline, in smokers vs. nonsmokers, 12:31-32
warfarin, effect of benzo(a)pyrene in rats, 12:38
warfarin, in smokers vs. nonsmokers, 12:38

PHARMACOLOGY

(See also PHARMACODYNAMICS; PHARMACOKINETICS)

carbon monoxide in establishing smoking habit, 15:7
cigarette smoke, 14:85, 14:94, 14:97-99
dependence and tolerance in maintenance of smoking habit, 15:14
nicotine in establishing smoking habit, 15:5, 15:7-8
tar in establishing smoking habit, 15:7
tobacco alkaloids, 14:94

PHARYNGEAL NEOPLASMS

(See also RESPIRATORY TRACT NEOPLASMS)

alcohol consumption and smoking and, 5:40-41
mortality in cigar vs. cigarette vs. pipe smokers, 13:22-23

PHENACETIN

effect of cigarette smoke on pharmacokinetics in rats, 12:28-29
effect of methylcholanthrene on pharmacokinetics in rats, 12:28-29
pharmacokinetics in smokers vs. nonsmokers, 12:28-29

PHENOLS

in cigarette smoke condensate, 14:52
effect of filters, 14:54
effect on ciliary activity, 14:81
levels in cigar vs. cigarette smoke, 13:11-12
levels in smoke of filtered vs. nonfiltered cigarettes, 14:57
reduction of levels in gas phase cigarette smoke, 14:106
structural formulae, 14:56

PHENYLBUTAZONE

effect of smoking on pharmacokinetics, 12:33

PHENYTOIN

pharmacokinetics in smokers vs. nonsmokers, 12:38

PHYSICAL ACTIVITY

(See also EXERCISE)

effect on coronary heart disease incidence in smokers, 4:38

PHYSICAL DEVELOPMENT

effect of maternal smoking on children, 1:21

PHYSICIAN VISITS

smokers vs. nonsmokers vs. ex-smokers, 3:15, 3:17

PHYSICIANS

as health educators, 22:15-16
role in cessation decision, 19:12-14, 21:11-12, 21:14, 22:19, 22:22
as role models, 22:6-8
in school antismoking programs, 20:9-10
smoking habits, 21:12, 22:9-14

Pipe

See SMOKE, PIPE; SMOKERS, PIPE; SMOKING, PIPE; TOBACCO, PIPE

PLACENTA

aryl hydrocarbon hydroxylase activity after maternal exposure to benzo(a)pyrene in rats, 8:66
effect of maternal smoking, 8:69
effect of maternal smoking, research needs, 8:78

PLACENTA PREVIA

gestational age and risk in smoking vs. nonsmoking mothers, 8:44, 8:46
maternal smoking levels and, 8:39
maternal smoking levels and perinatal mortality, 8:40

PLACENTAL RATIO

effect of maternal smoking, 8:14-18
effect of oxygen availability, 8:17
in smokers vs. nonsmokers, 8:15-16, 8:18

POLONIUM-210

cardiovascular diseases and, 4:62
levels in cigarette smoke, 14:60
levels in smokers vs. nonsmokers, 12:74-75
neoplasm induction in Syrian hamsters, 14:61
reduction in particulate phase cigarette smoke, 14:113
in tissues of smokers vs. nonsmokers, 14:60-61
as tobacco contaminant, 14:20-21

POLYCYTHEMIA

smoking in etiology of, 12:83

POLYMER FUME FEVER

(See also OCCUPATIONAL DISEASES)

smoking and, 7:5-6

PREECLAMPSIA

maternal smoking and, research needs, 8:77
maternal smoking levels and, 8:42

PREGNANCY

(See also PRETERM DELIVERY)
accidental hemorrhage in smokers vs. nonsmokers, 8:39
cessation of smoking during, 22:16, 22:18, 22:23
complications, research needs, 8:76-77

smoking and abruptio placentae and placenta previa, 8:39

smoking and bleeding, 8:39

smoking and premature membrane rupture, 8:39

gestational age and premature membrane rupture in smokers vs. nonsmokers, 8:44, 8:46

smoking levels and abruptio placentae, bleeding, placenta previa and premature membrane rupture, 8:39-41

smoking levels and perinatal mortality, 8:40

PRETERM DELIVERY

effect of maternal smoking levels, 8:43

and infant mortality risk in smoking vs. nonsmoking mothers, 8:42

maternal smoking and, 1:22

in smoking vs. nonsmoking mothers, 8:42

PREVENTION OF SMOKING

(See also ANTISMOKING CAMPAIGNS; CESSATION OF SMOKING)

communication models, 17:11-12
recommendations for the future, 17:22-25

summary of methodologies and programs, 1:33-34

Swedish 25-year program, 17:21-22
youth programs, 17:6, 17:17-22

PROPOXYPHENE

clinical effect in smokers vs. nonsmokers, 12:36-37

PROPRANOLOL

interactive effect with cigarette smoke on airways, 12:54

interactive effect with nicotine on cardiovascular system, 12:53

interactive effect with smoking on cardiovascular system, 12:37

PROSTAGLANDINS

effect of cigarette smoke on metabolism in lungs in rabbits, 12:39

PROTEINS

effect of smoking on metabolism, 12:65-66

synthesis, role in enzyme induction, 12:21-22

PROTONATION

nicotine in relation to pH, 14:86

- nicotine reduction and, 14:108
- PSYCHOMOTOR PERFORMANCE**
 - effect of carbon monoxide, 11:28, 11:34
 - nicotine deficit and, 16:8
- PUBLIC HEALTH CIGARETTE SMOKING ACT, A:7**
- Pulmonary alveolar macrophages**
 - See **MACROPHAGES, ALVEOLAR**
- Pulmonary clearance**
 - See **CILIARY ACTIVITY; LUNG FUNCTION**
- Pulmonary function**
 - See **LUNG FUNCTION**
- PYLORIC PRESSURE**
 - effect of smoking, 9:16
- RADIATION**
 - alpha exposure from radon as occupational hazard, 7:14
 - beta exposure as occupational hazard, 7:10
 - bladder neoplasms and smoking and, 12:90
 - and cigarette tars in neoplasm induction in mice, 7:10
 - laryngeal neoplasms and smoking and, 12:90
 - and smoking in lung neoplasm etiology, 5:28
 - synergistic effect with smoking on respiratory tract, 12:90
- RADIOELEMENTS**
 - levels in tobacco and tobacco smoke, 14:60
 - reduction in particulate phase cigarette smoke, 14:113
 - as tobacco contaminants, 14:20-21
- RADIUM-226**
 - levels in cigarette smoke, 14:60
 - as tobacco contaminant, 14:20-21
- Rapid smoking**
 - See **AVERSIVE THERAPY**
- RECIDIVISM**
 - carboxyhemoglobin levels as measure of, 15:29-30
 - cognitive and physiological factors, 16:18
 - post-treatment followup, 19:8
 - prevention, 19:30-31, 19:35
 - rates in cessation programs, 21:15-17
 - withdrawal state and, 16:18
- Reconstituted tobacco sheet**
 - See **TOBACCO SHEET**
- REFLEXES**
 - effect of nicotine, 14:92
- Relative molar potency**
 - See **MOLAR POTENCY**
- RELIGION**
 - church attendance and motivation for smoking, 18:11
 - effects of beliefs on tobacco consumption, 18:24
- RESPIRATORY FUNCTION TESTS**
 - (See also **LUNG FUNCTION**)
 - in smokers vs. nonsmokers vs. ex-smokers, 6:14-16
- RESPIRATORY SYMPTOMS**
 - in cigar and pipe smokers vs. nonsmokers, 13:34
 - in childhood and adult respiratory tract disease, 6:38-39
 - in cigar vs. cigarette vs. pipe smokers, 13:36-37
 - effect of air pollution in smokers vs. nonsmokers, 6:37
 - effect of smoking, 6:7
 - effect of smoking in children, 6:11-12
 - rate of decline of FEV in smokers vs. nonsmokers and, 6:22
 - in smokers vs. nonsmokers, 6:20
 - smoking and, summary of findings, 1:18-19
 - smoking and sex ratio, 6:20
 - smoking levels and, 6:20
 - in smoking vs. nonsmoking twins, 6:35
- RESPIRATORY SYSTEM**
 - (See also **LUNGS; TRACHEA**)
 - effect of cessation of smoking, 15:21
 - effect of inhalation in cigar and pipe smokers, 13:15-16
 - effect of nitrogen dioxide in rats, 14:81
 - effect of rapid smoking, 19:26
 - synergistic effect of uranium and smoking, 12:90
- RESPIRATORY TRACT DISEASES**
 - (See also **LUNG DISEASES**)
 - cessation of smoking in patients, 12:18-19
 - effect of involuntary smoking in children, 11:32

effect of parental smoking on incidence in children, 11:33-34
effect of smoking and history of childhood respiratory symptoms, 6:38-39
mass media preventive campaign, 21:10
smoking and, 6:7
smoking history of young adults and, 6:12
smoking in children and, 6:11-12
RESPIRATORY TRACT INFECTIONS
allergic predisposition and smoking, 10:22
effect of parental smoking on incidence in children, 10:12, 11:32
effect of passive smoking in infants, 8:45
effect of smoking on mortality, 2:41
in smokers vs. nonsmokers, 6:20
smoking levels and, 6:30
RESPIRATORY TRACT MUCOSA
effect of smoking, 10:14
RESPIRATORY TRACT NEOPLASMS
(See also **LARYNGEAL NEOPLASMS; LUNG NEOPLASMS; PHARYNGEAL NEOPLASMS; TRACHEAL NEOPLASMS**)
smoking in uranium miners and, 7:14
RNA
effect of methylcholanthrene on metabolism, 12:21-22
role in enzyme induction, 12:21-22
ROBERT WOOD JOHNSON FOUNDATION
Health Activities Project, 21:20
ROLE MODELS
(See also **PARENTAL SMOKING; PEER GROUPS; SIBLING SMOKING; TEACHERS; HEALTH PROFESSIONALS**)
in cessation of smoking, 18:21, 22:6-9
influence on smoking in adolescents, 17:11, 20:6, 21:11-14, 23:35
RUBBER
occupational hazards, 7:13
SALIVA
nicotine and thiocyanates in smokers vs. nonsmokers, 15:30
SAN DIEGO COMMUNITY LABORATORY
program description, 20:14-15, 21:25

SASKATOON SMOKING STUDY
description 20-11-12, 23:25
SATURATED FATS
in atherosclerosis induction in animals, 4:9
SCHICK SMOKING CONTROL CENTERS
cessation program, 21:16
SCHOOL HEALTH CURRICULUM PROJECT
community agency involvement, 23:15
curriculum development approach, 23:19
description, 20:18-22
evaluation, 17:19-20, 20:25
parental involvement, 21:19
teacher training, 23:21-23, 23:32
SCHOOL HEALTH EDUCATION STUDY
antismoking education component, 23:18
SCHOOL PROGRAMS
(See also names of individual programs)
antismoking education, 20:5-22
colleges, 21:9-11
curriculum theory, 23:16-22
effect on students' smoking habits, 17:15
evaluation, 17:18-21, 20:24-25, 23:23-25
influence on parents, 21:19-21
recommendations for the future, 23:36-39
smoking policies, 23:8-15
state health education laws, 23:5-7
teaching methods, 23:25-27
SECRETIN RELEASE
effect of nicotine, 9:14-15
effect of smoking, 9:15-16
SELF-REPORTS
(See also **VERBAL REPORT**)
carboxyhemoglobin levels as indicator of accuracy, 3:12
validity, 17:24, 19:6-7, 19:33, 21:23
SENSORY DEPRIVATION
cessation of smoking and, 19:18-19
SERUM IMMUNOGLOBULIN LEVELS
effect of smoking, 10:18
SERUM PRECIPITINS
in smokers vs. nonsmokers, 10:11

SEVENTH DAY ADVENTISTS

5-Day Plan (cessation program),
19:10, 21:15-16

SEX RATIO

absenteeism and, 3:8, 3:13
adolescent smoking, 17:7, 17:13,
18:16, 21:25
bed disability in smokers vs. non-
smokers, 3:12
bladder neoplasms in smokers, 5:45-
47
cessation of smoking and, 3:18, 18:21
cessation of smoking and alcohol con-
sumption, 18:20
cessation of smoking and personality,
18:17-18
chronic obstructive lung disease and,
6:7
consumption of cigarettes, cigars,
snuff, pipe and chewing tobacco
in the United States, 14:13
coronary heart disease morbidity ra-
tios in smokers vs. nonsmokers
vs. ex-smokers, 4:28-30
coronary heart disease mortality ra-
tios in smokers vs. nonsmokers,
4:24
effect of less hazardous cigarettes on
mortality, 2:24-25
heart conditions and, 3:19
high density lipoprotein levels in
smokers vs. nonsmokers, 4:61-62
laryngeal neoplasm risk in smokers
and ex-smokers, 5:33, 5:35-38
lung function, 6:21-22
lung function in ex-smokers, 6:23
lung neoplasm mortality ratio in low
tar and nicotine cigarette smok-
ers, 5:16-17
lung neoplasm mortality ratio in
smokers, 5:11-12
lung neoplasm risk in filtered vs. un-
filtered cigarette smokers, 5:16,
5:18-19
pancreatic neoplasm mortality and
risk ratios in smokers, 5:50-52
prevalence of acute conditions in
smokers vs. nonsmokers, 3:9
prevalence of chronic conditions in
smokers vs. nonsmokers, 3:7
prevalence of chronic obstructive pul-
monary disease, 6:20
recidivism and, 19:31

smoking and respiratory symptoms,
6:20
smoking and respiratory symptoms in
children, 6:11-12
smoking characteristics, 5:21, 5:23
smoking habit and neuroticism, 18:8
smoking habit and socioeconomic sta-
tus, 18:16
smoking habit in the United States,
5:19-21
smoking in blue- and white-collar
workers, 7:17
smoking levels and lung pathology,
6:27
snuff users in the United States,
13:10
Teenage Self Test scores, 20:22
tobacco chewers in the United
States, 13:10

SIBLING SMOKING

adolescents, 17:14
maintenance of smoking and, 18:15

Sidestream smoke

See **SMOKE, CIGARETTE SIDE-
STREAM; SMOKE STREAMS**

SLEEP

deprived vs. nondeprived smokers,
15:11

SMALL AIRWAYS FUNCTION

(See also **RESPIRATORY FUNC-
TION TESTS)**

chronic obstructive lung disease and,
6:11
effect of smoking levels, 6:13-19
pathological lesions of small airways
and, 6:18-19
screening methods for individuals at
high risk for chronic obstructive
lung disease, 6:12
in smokers vs. nonsmokers, 6:13
in smokers vs. nonsmokers vs. ex-
smokers, 6:14-16

SMOKE, CIGAR

(See also **SMOKERS, CIGAR;
SMOKING, CIGAR; TOBACCO, CI-
GAR)**

ammonia content, 14:39
aromatic hydrocarbon content, 13:11-
12
carbon monoxide content, 13:12,
14:38, 14:104
chemical analysis, 13:11-13
ciliotoxicity, 13:36-37

- effect of inhalation on respiratory tract, 13:15-16
- pH, 13:15-16
- phenol content, 13:12
- SMOKE, CIGARETTE**
 - (See also **SMOKERS; SMOKING; TOBACCO, CIGARETTE**)
 - alcohol content, 14:42
 - alkene content, 14:48
 - aldehyde content, 14:42
 - amine content, 14:41
 - aromatic hydrocarbon content, 14:41-42
 - benzene compound content, 14:49
 - carcinogenic PAH activity, 14:54
 - chemical composition percent distribution, 14:35
 - constituents, and biological response, 14:26
 - constituents, research recommendations, 14:120
 - effect of cigarette manufacturing on constituents, 14:28-30
 - effect of constituents on enzyme activity, 12:7
 - effect of static burning temperature, 14:36
 - effect on antibody response in mice, 12:59
 - effect on central nervous system, 15:11
 - effect on immunoglobulins, 6:31-32
 - effect on lung function, 14:90
 - effect on macrophages, 6:29-30
 - effect on mucociliary system, 6:32-33
 - effect on phagocytic activity of alveolar macrophages, 10:17
 - effect on phenacetin pharmacokinetics in rats, 12:28-29
 - effect on prostaglandin F-2a metabolism in lungs in rabbits, 12:39
 - effect on systemic humoral immunity in mice, 10:18
 - free fatty acid levels, 14:55
 - heterocyclic compounds, 14:52, 14:57
 - hydrazine levels, 14:41
 - ketone levels, 14:42
 - naphthalene levels, 14:51
 - nickel levels, 14:59
 - nicotine levels, effect on blood pressure, 14:87
 - nicotine metabolites, 14:93-94
 - nitrile levels, 14:40
 - nitrogen compound levels, 14:41
 - nitrosamine precursors, 14:41
 - nonvolatile nitrosamine levels, 14:45
 - pharmacology, 14:85, 15:5
 - phenol levels, 14:57
 - physical and chemical nature, 14:35
 - polynuclear aromatic hydrocarbon indicators, 14:111
 - polynuclear aromatic hydrocarbons, 14:51
 - radioelements, 14:60
 - reaction mechanisms, 14:9
 - reduction of toxicity, 14:104, 14:108
 - relative molar potency of alkaloids, 14:96
 - retention in buccal cavity and respiratory tract, 12:7
 - standard smoking conditions for analysis, 14:35
 - structural formulae of pesticide residues, 14:62
 - sulfur compounds levels, 14:40
 - summary of gas and particulate phase constituents, 1:29-30
 - summary of toxic and carcinogenic constituents, 1:30
 - toxicity reduction methods, 14:114
 - weakly acidic heterocyclic compounds structural formulae, 14:56
- SMOKE, CIGARETTE MAINSTREAM**
 - (See also **SMOKE STREAMS**)
 - alkane content, 14:48
 - amine content, 14:47
 - ammonia content, 14:39
 - arsenic content, 14:59
 - cadmium content, 14:60
 - catechol content, 14:53
 - chemical composition, 14:35
 - ciliotoxicity and, 14:105
 - cyanide content, 14:39-40
 - humectant content, 14:63
 - nicotine content, 14:45
 - nitrogen oxide content, 14:39
 - phenol content, effect of filters, 14:106
 - tar content determination, 14:43
 - temperature profile, 14:36
- SMOKE, CIGARETTE SIDESTREAM**
 - (See also **SMOKE STREAMS**)
 - alkane content, 14:48
 - amine content, 14:39, 14:41, 14:47
 - catechol content, 14:54
 - chemical composition, 14:38

nicotine content, 14:45
tar content, 14:44
temperature profile, 14:36

Smoke exposure

See **SMOKE INHALATION**

SMOKE CONDENSATES

(*See also* **SMOKE, TOBACCO; TARS, TOBACCO**)

benzo(a)pyrene content, 14:112
carcinogenicity, 13:30-32
carcinogenicity of experimental cigarettes in mice, 14:30
cigar, alkaloid content, 13:11
cigar, aromatic hydrocarbon content, 13:11-12
cigar, nicotine content, 13:12
cigar, phenol content, 13:11-12
effect of cigarette manufacturing on composition, 14:28-30
effect on antiprotease activity in vitro, 6:28
effect on elastase release from lungs in rats, 6:29
effect on enzyme release from polymorphonuclear leukocytes, 6:28
phenol content, 14:52
role of cigarette manufacturers in control of constituents, 14:9

SMOKE INHALATION

(*See also* **SMOKING**)

effect of cigar and pipe smoke pH, 13:15-16
effect of switching tobacco products on patterns, 13:18-19
effect on arterioles in dogs, 4:18
effect on blood pressure in cats, 14:77
effect on carboxyhemoglobin levels in cigar and pipe smokers, 13:18
effect on cigarette smoke retention in buccal cavity, 12:7
effect on coronary heart disease mortality ratios, 4:37
effect on enzymes in dogs, 14:78
effect on exercise tolerance in rats, 14:77
effect on hemodynamics in dogs, 14:76
effect on leukocyte count, 8:82
effect on lung neoplasm mortality ratio, 5:14-15
effect on lung neoplasm mortality ratio in women, 5:21-22

effect on lungs in dogs, 14:76
effect on lungs in monkeys, 14:76
effect on mortality, 2:20-21
effect on mortality in cigar and pipe smokers, 13:18
effect on mortality ratio, 2:22-24
effect on mortality ratio in women, 2:26-27
effect on myocardial infarct morbidity and mortality, 4:35
effect on nicotine absorption in cigar smokers, 13:16-17
effect on pregnant rats, 8:10-11
effect on respiratory system in cigar and pipe smokers, 13:15-16
effect on tolerance in dogs, 15:16
exercise in dogs and, 14:78
exposure methodology, 14:73-74
in laryngeal neoplasm induction in hamsters, 5:34
males vs. females, 5:21, 5:23
maternal, effect on mother and fetus in sheep, 8:53
maternal, effect on offspring in rats, 8:10-11
in myocardial infarct induction in dogs, 14:77
patterns in cigar vs. cigarette vs. pipe smokers in Great Britain, 13:18-19
patterns in the United States, 2:33

SMOKE, PIPE

(*See also* **SMOKERS, PIPE; SMOKING, PIPE; TOBACCO, PIPE**)

aromatic hydrocarbon content, 13:11-12

pH, 13:15-16

SMOKE STREAMS

(*See also* **SMOKE, CIGARETTE MAINSTREAM; SMOKE, CIGARETTE SIDESTREAM**)

carbon monoxide content, 11:15
involuntary smoking and, 11:5
ratio of constituents in main- vs. sidestream smoke, 11:6

SMOKE WATCHERS

cessation program, 21:16

SMOKENDERS

cessation program, 21:16
followup evaluation, 19:11

SMOKE, TOBACCO

(*See also* **SMOKE, CIGAR; SMOKE, CIGARETTE; SMOKE, PIPE; SMOKING**)

absorption of constituents by non-smokers, 11:6, 11:15
in allergy etiology, 10:23-24
amine and nitrosamine content, 12:74
amine content, 14:47
antigens, identification of, 10:11
carcinogens, ciliotoxic agents and tumor promoters in gas phase, 5:54-55
carcinogens, cocarcinogens and tumor promoters in particulate phase, 5:54-57
constituents, correlation with tobacco leaf characteristics, 14:24
effect of exposure in allergic children and adults, 10:14, 10:21
effect of leaf components, 14:11
effect on alveolar macrophages, 6:30-31, 10:15-16
effect on blood lipid levels in animals, 4:61
effect on cardiovascular system in animals with myocardial infarct, 4:45
effect on cellular and humoral immunity, 6:30-31
effect on ciliary function, 10:14-15
effect on enzyme activity, 12:27-28, 12:75-76
effect on enzyme systems, 10:16
effect on fetal weight and birth weight in animals, 8:52
effect on fetal weight and maternal food intake in rats, 8:52-53
effect on fetus, research needs, 8:79
effect on immune system, 10:5, 10:17
effect on lymphocytes in mice, 10:19
effect on metabolism of food constituents and additives, 12:75-76
effect on nonsmokers, 11:25
effect on pre-existing allergies, 10:13
effect on pregnant animals, 8:52
effect on rat fetus, 8:53
effect on tracheobronchial clearance in dogs, 10:15
eye irritation and, 10:21
heterocyclic compound carcinogens structural formulae, 14:55

measurement of constituents in enclosed spaces, 11:7-14
measurement of constituents under natural conditions, 11:16-20
metal levels, 14:58-59
in neoplasm induction in animals, 1:17
nickel levels, 14:59
pesticide residues, 12:75
radioelement levels, 14:60
skin test reactions, 10:13

SMOKERS

(*See also* **SMOKERS, CIGAR; SMOKERS, PIPE**)

B and T cell count and ratio, 10:19
granular leukocyte levels, 10:20

SMOKERS, CIGAR

(*See also* **SMOKE, CIGAR; SMOKING, CIGAR; TOBACCO, CIGAR**)

blood cholesterol levels, 4:61
bronchitis and emphysema mortality, 13:34
cardiovascular disease mortality ratio, 13:33
chronic obstructive pulmonary disease mortality ratio, 13:35
coronary heart disease mortality ratio, 4:22-23
effect of inhalation on mortality, 13:18
esophageal neoplasm mortality, 13:24-25
esophageal neoplasm mortality ratio, 5:43
inhalation patterns in Great Britain, 13:18
leukocyte count, 12:81
lung neoplasm mortality rates, 5:23
lung neoplasm mortality ratio, 13:26-28
mortality, 13:13-14
myocardial infarct morbidity and mortality, 4:35
oral neoplasm mortality ratio, 13:21
relative risk ratio for lip neoplasms, 13:22
relative risk ratio for lung neoplasms, 13:29-30
respiratory symptoms, 13:34
thrombosis mortality rates, 4:59
in the United States, 13:9

SMOKERS, PIPE

(See also **SMOKE, PIPE; SMOKING, PIPE; TOBACCO, PIPE**)

- blood cholesterol levels, 4:61
- bronchitis and emphysema mortality, 13:34
- cardiovascular disease mortality ratio, 13:33
- chronic obstructive pulmonary disease mortality ratio, 13:35
- coronary heart disease mortality ratio, 4:22-23
- effect of inhalation on mortality, 13:18
- effect of inhalation on respiratory tract, 13:15-16
- esophageal neoplasm mortality, 13:24-25
- esophageal neoplasm mortality ratio, 5:43
- inhalation patterns in Great Britain, 13:18
- leukocyte count, 12:81
- lung neoplasm mortality rates, 5:23
- lung neoplasm mortality ratio, 13:26-28
- mortality, 13:13-14
- myocardial infarct morbidity and mortality, 4:35
- oral neoplasm mortality ratio, 13:21
- relative risk ratio for lip neoplasms, 13:22
- relative risk ratio for lung neoplasms, 13:29-30
- respiratory symptoms, 13:34
- thrombosis mortality rates, 4:59
- in the United States, 13:9

SMOKERS VS. NONSMOKERS

(See also **NONSMOKERS**)

- abruptio placentae, placenta previa, and bleeding during pregnancy, 8:39
- absenteeism, 3:8, 3:10, 3:13
- accidental hemorrhage in pregnancy, 8:39
- activity limitation, 3:13-14
- acute conditions, 3:6
- air pollution and chronic obstructive lung disease, 6:36
- air pollution and lung pathology, 6:36
- alcohol consumption and drug use, 12:41

- alpha-1-antitrypsin deficiency and emphysema, 6:34
- alveolar macrophage migration, 6:31
- angina pectoris morbidity ratios, 4:48
- annual probability of dying, 2:30-34
- antibody response to viral vaccines, 12:58-59
- antipyrine pharmacokinetics, 12:29-31
- anxiety levels, 16:7-8
- Arthus skin test characteristics, 10:10
- asphyxia in infants of, 8:69
- atherosclerosis, 4:10-12, 4:14-16
- B and T lymphocytes, 6:31
- bed disability, 3:12
- bicarbonate levels in infants of, 8:69
- bilirubin levels, 12:34
- birth weight of infants of, 8:11, 8:14-17, 8:20-21
- bladder neoplasm mortality ratio, 5:45-46
- blood calcium levels, 12:84
- blood cholesterol levels, 4:61-62
- blood circulation, 15:12-13
- blood coagulation, 12:84-85
- blood glucose levels, 12:84
- blood lipid levels, 12:83-84
- blood pressure, 4:57
- blood protein levels, 12:84
- breast feeding, 8:48
- bronchitis in gold miners, 7:15
- bronchitis prevalence by occupations, 6:39
- carboxyhemoglobin levels and carbon monoxide occupational exposure, 7:8
- carboxyhemoglobin levels in infants of, 8:69
- carcinoembryonic antigen levels, 12:61-62, 12:86
- cardiovascular disease mortality ratios in Japan, 4:21, 4:34-35
- cerebrovascular disease mortality rates and ratios in males vs. females, 4:51
- chronic obstructive lung disease and mortality, 6:9-10
- ciliary function, 10:15
- clinical effects of propoxyphene, 12:36-37
- clinical effects of selected drugs, 12:36-37
- coronary heart disease morbidity ratios, 4:27-33, 4:36-37

coronary heart disease mortality ratios, 4:22-26, 4:36-37
 definition, 23:24
 drug use patterns, 18:13-15
 duration of gestation, 8:18
 effect of behavior and personality on pharmacokinetics, 12:40-41
 elastase release from macrophages, 6:30
 emphysema, 6:25-26
 emphysema and lung pathology, 6:23-24
 erythrocyte parameters, 12:82-83
 esophageal neoplasm mortality ratio, 5:42-43
 ethanol pharmacokinetics, 12:39
 etiology of fetal and neonatal death, 8:38
 etiology of perinatal death, 8:36
 etiology of stillbirth, 8:37
 fibrosis in asbestos workers, 7:12
 gastric secretion in, 9:13
 gestational age and infant mortality, 8:43, 8:45
 gestational age and risk for abruptio placentae, placenta previa and premature membrane rupture, 8:44, 8:46
 gestational age and risk for preterm delivery, 8:44
 gestational age at birth of infants of, 8:43
 glutethimide pharmacokinetics, 12:33
 growth and development of children of, 8:21-23
 heart conditions, 3:16-17, 3:19
 head circumference in infants of, 8:20-21
 hematocrit in infants of, 8:69
 high density lipoprotein levels in males vs. females, 4:61-62
 histologic changes in esophagus, 5:44
 hospitalization, 3:14-16
 hyaline thickening in small arteries and arterioles in myocardium, 4:16
 hypertension, 4:57
 immunoglobulin containing cell counts in lobar bronchi, 10:17
 immunoglobulin levels, 6:31-32
 infant mortality, 8:27, 8:34
 infant mortality risk, 8:31
 infarct mortality risk in black vs. white mothers, 8:30
 job accident rates, 7:15
 kidney, liver, and lung weights, 12:9
 kidney neoplasm mortality and risk ratios, 5:48-49
 lactation, 8:48
 laryngeal neoplasm mortality ratio, 5:32-33
 learning, 15:19
 leukocyte count, 2:79-82
 level of well-being, 3:18
 long-term study of children of, 8:22-23
 lung diseases in rubber workers, 7:13
 lung function, 6:21
 lung function after cadmium exposure, 7:15
 lung function in black vs. white vs. oriental men and women, 6:21
 lung function in chlorine workers, 7:10
 lung function in cotton workers, 7:9
 lung function in miners, 7:9
 lung neoplasm mortality and asbestos exposure, 7:11
 lung neoplasm mortality in twins, 5:23
 lung neoplasm mortality ratio in males vs. females, 5:11-12
 lung neoplasm mortality ratio in women, 5:20-22
 lung neoplasm risk in asbestos factory workers, 7:11-12
 lung neoplasm risk in insulation workers, 7:11
 lung neoplasms in chloromethyl ether workers, 7:16
 lung neoplasms in uranium miners, 7:14
 lung pathology, 6:24-27
 lung pathology in sudden death victims, 6:18
 macrophage count and ultrastructure, 10:16
 macrophages in bronchopulmonary lavage fluid, 6:29
 maternal weight gain and fetal growth, 8:24-25
 meperidine clearance, 12:39
 mortality in twins, 2:42
 mortality rates, 2:15
 myocardial infarct in women, 12:52

myocardial infarct morbidity and mortality, 4:35-36
neonatal mortality, 8:40
nicotine and cotinine content in urine, 11:24
nicotine content in plasma, 11:24
nicotine content of breast milk in lactating mothers, 8:51
nicotine content of saliva, 15:30
nicotine levels in urine, 15:29
nicotine metabolism, 15:16, 15:9
nitric oxide levels, 14:80
nortriptyline pharmacokinetics, 12:39
obstructive airway diseases in miners, 7:9
oral neoplasm mortality ratio, 5:39-40
osteoporosis, 12:67
pancreatic neoplasm mortality and risk ratios, 5:50-52
pentazocine dosage requirements, 12:36
peptic ulcer healing, 9:9-10
peptic ulcer incidence, 9:5-6
peptic ulcer mortality rates, 9:11
peptic ulcer prevalence, 6:7-8
peptic ulcer prevalence ratios in six countries, 9:8
peptic ulcer size and recurrence, 9:9
perception of health status, 3:14-15
perinatal mortality, 8:35, 8:40
perinatal mortality and maternal age, parity, and education, 8:33
perinatal mortality risk for infants of, 8:32
peripheral vascular disease in diabetics, 4:53
personality, 18:5-10
phagocytic activity of alveolar macrophages, 10:17
phenacetin pharmacokinetics, 12:28-29
phenytoin pharmacokinetics, 12:38
physician visits, 3:14, 3:17
placental changes, 8:69
placental ratios, 8:18
polonium-210 levels in tissues, 10:60-61
preeclampsia and toxemia in pregnancy, 8:42
pregnancy weight gain and fetal growth, 8:24
premature membrane rupture during pregnancy, 8:39
preterm delivery and infant mortality risk, 8:42
prevalence of acute conditions, 3:9
prevalence of chronic conditions, 3:7
prognosis following vascular grafting, 4:53
protease activity of macrophages, 6:29
proteinuria after cadmium exposure, 7:15
rate of decline of FEV and respiratory symptoms, 6:22
respiratory symptoms in twins, 6:35
respiratory tract diseases in young adults, 6:12
respiratory tract infections, 6:20
respiratory tract neoplasms in uranium miners, 7:14
respiratory tract symptoms, 6:20
response to diagnostic tests, 12:79
risk of low birth weight in infants of, 8:13
serum albumin, uric acid, and creatinine concentration, 12:40, 12:84
serum precipitins in, 10:11
skin test reactions to tobacco leaf extracts, 10:13
small airways function, 6:13-16
socioeconomic status and chronic obstructive lung diseases, 6:38
spontaneous abortion, 8:30-32
stillbirth incidence, 8:36
sudden cardiac death, 4:43-44
sudden infant death syndrome in infants, 8:45
T cell counts, 10:19
theophylline pharmacokinetics, 12:31-32
thiocyanate levels in saliva, 15:30
thiocyanates in plasma, 7:7
thiocyanates in urine, 7:7
thrombosis mortality rates, 4:59
tolerance to cigarette smoke, 15:16-17
trace metal levels, 12:73-74
tryptophan metabolism, 12:67
umbilical artery changes, 8:69
vitamin B₁₂ levels in pregnancy, 8:73
vitamin C levels in breast milk of lactating mothers, 8:52
vitamin C levels in pregnancy, 8:74
vitamin C levels in serum, 12:34
warfarin metabolism, 12:55